Recombinant human growth hormone vs placebo
- Recombinant human growth hormone for treating burns and donor sites 2014 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 99 participantsLow
The intervention showed no clear difference in oedema ‐ Day 1 Scale 1 to 4 (low certainty).
The intervention showed no clear difference in ecchymosis ‐ Day 1 Scale 1 to 4 (low certainty).
It is very uncertain whether continuous skin sutures changes superficial surgical site infection compared with interrupted skin sutures (very low certainty).
Continuous skin sutures may leads to lower superficial wound dehiscence compared with interrupted skin sutures (low certainty).
It is very uncertain whether subcutaneous closure changes superficial surgical site infection compared with no subcutaneous closure (very low certainty).
It is very uncertain whether subcutaneous closure changes superficial wound dehiscence compared with no subcutaneous closure (very low certainty).
It is very uncertain whether subcutaneous closure changes deep wound dehiscence compared with no subcutaneous closure (very low certainty).
G‐CSF + standard treatment may leads to higher improvement of infection clinical and microbiological assessment compared with usual treatment (low certainty).
G‐CSF + standard treatment may leads to lower need for surgery: Overall Surgical Interventions compared with usual treatment (low certainty).
G‐CSF + standard treatment may leads to lower need for surgery: Amputation compared with usual treatment (low certainty).
Fibrous‐hydrocolloid (hydrofibre) dressing showed no clear difference in number of ulcers healed compared with basic wound contact dressing (moderate certainty).
Hydrogel dressings probably leads to higher number of ulcers healed compared with basic wound contact dressings (moderate certainty).
Hydrogel dressings showed no clear difference in number of ulcers healed compared with larval therapy (low certainty).